ARQT
Arcutis Biotherapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Price History
Fundamentals
| Market Cap | $3.28B |
| P/E Ratio (TTM) | - |
| Forward P/E | 22.69 |
| EPS (TTM) | $-0.02 |
| Dividend Yield | - |
| Profit Margin | -0.57% |
| Revenue Growth | 60.10% |
| ROE | -1.43% |
| Debt/Equity | 60.47 |
| Recommendation | None |
| Analyst Target | $34.63 |
| Analysts | 8 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 72.7 |
| Beta | 1.52 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $31.77 |
| 52-Week Low | $13.06 |
| 50-Day Avg | $23.04 |
| 200-Day Avg | $24.29 |
| Avg Volume | $1.72M |
| Volume | $1.29M |
Performance Analysis
BULLISHARQT shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report